Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 7/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1348967 | 0.79 | ALDH1A1 (0.35) | CYP3A4RAB9AEIF4A3 | |
| SCHEMBL1358332 | 0.76 | CYP3A4 (0.37) | KMT2ACYP3A4EPHX2PIK3CDKDM1A | |
| SCHEMBL1359903 | 0.76 | CYP3A4 (0.37) | KMT2ACYP3A4EPHX2PIK3CDKDM1A | |
| SCHEMBL1358334 | 0.76 | CYP3A4 (0.37) | KMT2ACYP3A4EPHX2PIK3CDKDM1A | |
| SCHEMBL1359909 | 0.75 | CYP3A4 (0.39) | MEN1KMT2ACYP3A4 | |
| SCHEMBL1702346 | 0.68 | TDO2 (0.41) | — | |
| SCHEMBL1542602 | 0.68 | CYP3A4 (0.53) | CYP3A4 | |
| SCHEMBL1542257 | 0.67 | CYP3A4 (0.61) | CYP3A4 | |
| SCHEMBL1358011 | 0.67 | CYP3A4 (0.37) | CYP3A4 | |
| SCHEMBL1359499 | 0.67 | CYP3A4 (0.37) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480533-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8063072-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2011033045-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LI JIM | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | PDK2 2070/4885MEN1 4722/4885KMT2A 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.